XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
  Anti-Inflammatory
  Antivirals
  Antihypertensives
  Anticholesterol
  Anti-Clotting Drugs
  Anti Cancer Drugs
  Hypnotics
  PPI
  Antibiotics
  Analgesics
  Surfactants
  Fatty Acids
  Adrenergics
  Metals
  Varenicline
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Pharmacology Channel
subscribe to Pharmacology newsletter

Latest Research : Pharmacology

   DISCUSS   |   EMAIL   |   PRINT
Prescribing Information for Galantamine Hydrobromide Updated Following Deaths in Subjects with Mild Cognitive Impairment (MCI)
Apr 2, 2005, 20:26, Reviewed by: Dr.

REMINYL is approved only for the treatment of mild to moderate Alzheimer�s Disease. No indication is being sought for the treatment of individuals with mild cognitive impairment.

 
Ortho-McNeil Neurologics modified the PRECAUTIONS section of the Prescribing Information for Reminyl, approved only for the treatment of mild to moderate Alzheimer's Disease.

The changes provide new safety information regarding the results of two randomized, placebo-controlled trials of 2 years duration in subjects with mild cognitive impairment(MCI). A total of 13 subjects on REMINYL (n=1026) and 1 subject on placebo (n=1022) died.

The deaths were due to various causes which could be expected in an elderly population. About half of the REMINYL deaths appeared to result from various vascular causes (myocardial infarction, stroke), and sudden death.

Read the complete MedWatch 2005 Safety summary, including a link to the Dear Healthcare Professional letter below:

March 31, 2005

Dear Healthcare Professional:

The REMINYL� (galantamine hydrobromide) Prescribing Information has been updated with the addition of the following information regarding the results of two investigational studies of REMINYL in individuals with mild cognitive impairment.

REMINYL is approved only for the treatment of mild to moderate Alzheimer�s Disease. No indication is being sought for the treatment of individuals with mild cognitive impairment.

PRECAUTION

Deaths in Subjects with Mild Cognitive Impairment (MCI)

In two randomized, placebo-controlled trials of 2 years duration in subjects with mild cognitive impairment (MCI), a total of 13 subjects on REMINYL� (n=1026) and 1 subject on placebo (n=1022) died. The deaths were due to various causes which could be expected in an elderly population; about half of the REMINYL� deaths appeared to result from various vascular causes (myocardial infarction, stroke, and sudden death).

Although the difference in mortality between REMINYL� and placebo-treated groups in these two studies was significant, the results are highly discrepant with other studies of REMINYL�.

Specifically, in these two MCI studies, the mortality rate in the placebo-treated subjects was markedly lower than the rate in placebo-treated patients in trials of REMINYL� in Alzheimer�s disease or other dementias (0.7 per 1000 person years compared to 22-61 per 1000 person years, respectively).

Although the mortality rate in the REMINYL�-treated MCI subjects was also lower than that observed in REMINYL�- treated patients in Alzheimer�s disease and other dementia trials (10.2 per 1000 person years compared to 23-31 per 1000 person years, respectively), the relative difference was much less.

When the Alzheimer�s disease and other dementia studies were pooled (n=6000), the mortality rate in the placebo group numerically exceeded that in the REMINYL� group. Furthermore, in the MCI studies, no subjects in the placebo group died after 6 months, a highly unexpected finding in this population.

Individuals with mild cognitive impairment demonstrate isolated memory impairment greater than expected for their age and education, but do not meet current diagnostic criteria for Alzheimer�s disease.

IMPORTANT PRESCRIBING INFORMATION

These investigational trial results have been presented at international scientific meetings as well as in a press release, and also have appeared on Health Authority web sites in many countries of the world. Ortho-McNeil Neurologics, Inc.,* remains committed to providing you with the most current product information available for the management of your patients.

Please refer to the enclosed package insert for full Prescribing Information. As always, we request that serious adverse events be reported to Ortho-McNeil Neurologics at 1-800-526-7736 or to the FDA MedWatch program by phone (1-800-FDA-1088), by fax (1-800-FDA-0178), or by email (www.fda.gov/medwatch). For additional medical information about REMINYL or any other Ortho-McNeil Neurologics, Inc. products, please call 1-800-526-7736 from 9AM to 5PM EST, Monday through Friday.

Sincerely,
Joseph Hulihan, MD
Vice President, Medical Affairs
Ortho-McNeil Neurologics, Inc.
 

- U.S. Food and Drug Administration (FDA)
 

 
Subscribe to Pharmacology Newsletter
E-mail Address:

 

Please refer to the enclosed package insert for full Prescribing Information. As always, we request that serious adverse events be reported to Ortho-McNeil Neurologics at 1-800-526-7736 or to the FDA MedWatch program by phone (1-800-FDA-1088), by fax (1-800-FDA-0178), or by email (www.fda.gov/medwatch). For additional medical information about REMINYL or any other Ortho-McNeil Neurologics, Inc. products, please call 1-800-526-7736 from 9AM to 5PM EST, Monday through Friday.

Contacting MedWatch
U.S. Food and Drug Administration
MedWatch Office, 5600 Fishers Lane, HFD-410
Rockville, MD 20857
Fax: 301-827-7241

* REMINYL was formerly marketed by Janssen Pharmaceutica Products, L.P., a sister company also headquartered in Titusville, N.J.
01RM577


Related Pharmacology News

Phase Ib Trial Is Evaluating Bavituximab Administered With Common Chemotherapy Regimens
Two-component lantibiotic with therapeutic potential discovered
Prescription pain medication abuse on rise
Antibiotic inhibits cancer gene activity
NRTIs limits the atherogenic side effect of the protease inhibitors
Cyclin-dependent kinase inhibitors: The latest anti-inflammatory
FDA requested to promptly approve 17-P to prevent premature birth
Rapamycin shown to inhibit angiogenesis
Tigecycline, world�s first glycylcycline expanded broad-spectrum antibiotic, launched in UK
Ibuprofen - worsening cognitive function


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us